LBT (ASX) Crunch Time

Originally posted by Callahan70 ↑

2016 AGM it was clearly stated

Discussions continue with global partner(s.) Increased interest post FDA Clearance. Timing of Letter Of Intent to be decided.

Signing of alliance/distribution agreement with global partners(s) for APAS

APAS Independence first Commercial sale by Global Alliance Partner

2017 AGM it was clearly stated

Signing of distribution agreement for APAS

2018 AGM is fast approaching

What will they say this year Signing of distribution agreement for APAS early 2019

I look at

Nanosonics with 299.2 million shares on issue a market cap of 1.1 billion and a shareprice of $ 3.60

Resapp Health with 659 Million shares on issue a market cap of 156 million and a share price of $ 0.22 doesn’t even have a product If we had a market cap of 156 million our share price would be $ 0.78

Then LBT with 201 million shares on issue and a market cap of 21 Million and a share price of $ 0.105

Something has to happen before AGM some objectives have to be met. I don’t want to hear about heavy lifting if you will, we need some results.

Some board members have been presiding over LBT for 12 years no less, unheard of these days and we have achieved very little, We need some more dynamic people on the board like Glenn Haifer and we need management to achieve some objectives.

We don’t even have a microbiologist on the board.

The current chair has been there since the original IPO at 0.20 and today we sit here at $ 0.105

If they had concentrated on getting the share price up, the options at 0.44 that expire in Nov and Dec might have been taken up which would of added 6 Million to the bottom line at a heathy price not these cap raises at 0.15

They can’t go to another AGM and present the next 12 months objectives when they haven’t achieved any from the year before.

CY18 Key Objectives as per 2017 AGM Presentation were

Extend APAS analysis modules Not done yet, That we know

Sales of APAS in Australia and NZ Only one sale

Sales of APAS in targeted European countries No sales achieved

Sales of APAS in USA No Sales achieved

Signing of distribution agreement Not done yet

FDA 510K supplement cleared for APAS Independence Not done yet

CE Marking for APAS No word

Market research for Woundvue Shelved

RAH 6 month review of Woundvue No word

These were all in the AGM presentation

12 months and none of the objectives have been met.

Its crunch time, time for results and it has to be before the AGM.

Current market cap lower than just the development cost of APAS.

It’s now or never. RESULTS must be forth coming

They have a wonderful machine, great AI, patented and proven and potential royalties of $60,000,000 on just 1500 machines. Never mind the profit share on the sales of the machine.

In my humble opinion.

60 million puts this young pup in the realms of a young cochlear.

The company has a future, but it has to start meeting objectives.

Expand

All great points and many of us agree with you.

Where is the push coming from though to turn our valid greivences from words into actions.

Where are the BIG shareholders that collectively control 50.1% of the issued capital calling for an EGM to dump the board?

No.	Vol.	Price($)
4	776749	1.7¢

No.

Vol.

Price($)

776749

1.7¢

Price($)	Vol.	No.
1.8¢	238095	1

Price($)

Vol.

No.

1.8¢

238095

No.	Vol.	Price($)
1	2173	0.082
1	888	0.076
1	28682	0.070
1	5000	0.065
1	100000	0.062

No.

Vol.

Price($)

2173

0.082

888

0.076

28682

0.070

5000

0.065

100000

0.062

Price($)	Vol.	No.
0.083	32748	1
0.084	58888	1
0.087	28000	1
0.089	50000	1
0.090	89000	2

Price($)

Vol.

No.

0.083

32748

0.084

58888

0.087

28000

0.089

50000

0.090

89000

(20min delay)
Last 1.7¢		Change -0.001(5.56%)		Mkt cap ! $23.13M

Open	High	Low	Value	Volume
1.8¢	1.8¢	1.7¢	$13.20K	747.0K

Crunch Time, page-10

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Chaos reigns markets – so let's take stock of where we're at ahead of December

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Buyers (Bids)

Sellers (Offers)

Crunch Time, page-10

Top Stories

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Chaos reigns markets – so let's take stock of where we're at ahead of December

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Buyers (Bids)

Sellers (Offers)